Table 2.
Association between the reason for discontinuation of the first TNFi and response to the second TNFi over time
| Reason to discontinue the first TNFi* | Outcome for the second TNFi OR (95% CI) | ||||
|---|---|---|---|---|---|
| ASDAS-CII (n = 135) | ASDAS-MII (n = 135) | ASDAS-LDA (n = 166) | ASDAS-ID (n = 166) | BASDAI50 (n = 147) | |
| (Ref. primary failure) | |||||
| -Secondary failure | 1.9 (0.7; 4.8) | 4.8 (1.3; 18.2) | 1.2 (0.6; 2.4) | 7.3 (1.9; 27.7) | 1.4 (0.6; 3.0) |
| -Adverse events | 1.5 (0.6; 3.5) | 2.4 (0.6; 9.6) | 0.9 (0.5; 1.7) | 9.1 (2.5; 33.3) | 1.1 (0.5; 2.3) |
| -Others | 1.0 (0.3; 3.8) | 1.7 (0.1; 19.4) | 1.0 (0.4; 2.4) | 7.7 (1.6; 37.9) | 0.5 (0.1; 1.7) |
ASDAS Ankylosing Spondylitis Disease Activity Score, LDA low disease activity, ID inactive disease, CII clinically important improvement, MII major important improvement, BASDAI50 Bath Ankylosing Spondylitis Disease Activity Index 50, N number
*Generalized estimated equation (GEE) models with the reason for discontinuation of the first tumor necrosis factor inhibitor (TNFi) as a predictor (reference category: primary failure); all models adjusted for age, gender, and C-reactive protein. Models include all visits during follow-up of up to 10 years. Odds ratios (OR) in bold are statistically significant (p < 0.05)